Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of IBB0979 plus topotecan versus topotecan in relapsed small cell lung cancer
CTR20253060Phase 2Active
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Aug 2025
- Modality
- Small Molecules, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IBB0979, topotecan in small cell lung cancer (SCLC), sponsored by SUNHO BioPharmaceutical. Started Aug 2025; status: active.
02
Drugs
IBB0979topotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20253060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253060.